Natalizumab for relapsing-remitting multiple sclerosis;Natalizumab para la esclerosis múltiple remitente-recurrente

Neurologia

Volumn 26, Issue 6, 2011, Pages 357-368

  Horga, A ^a   Tintore M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Clinical trial; Monoclonal antibody; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

NATALIZUMAB;

DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERSENSITIVITY REACTION; MONOTHERAPY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD-BRAIN BARRIER; CELL MOVEMENT; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LEUKOCYTES; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959883248     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2010.10.004     Document Type: Short Survey

References (76)

1. Compston A., Coles A. Multiple sclerosis. Lancet. 2002, 359:1221-1231.
2. Pugliatti M., Rosati G., Carton H., Riise T., Drulovic J., Vécsei L., et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006, 13:700-722.
3. Kantarci O.H. Genetics and natural history of multiple sclerosis. Semin Neurol. 2008, 28:7-16.
4. Hemmer B., Hartung H.P. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol. 2007, 62:314-326.
5. Compston A., Coles A. Multiple sclerosis. Lancet. 2008, 372:1502-1517.
6. Von Andrian U.H., Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003, 348:68-72.
7. Rice G.P., Hartung H.P., Calabresi P.A. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005, 64:1336-1342.
8. Horga A., Horga de la Parte J.F. Natalizumab en el tratamiento de la esclerosis múltiple. Rev Neurol. 2007, 45:293-303.
9. Del Pilar Martin M., Cravens P.D., Winger R., Frohman E.M., Racke M.K., Eagar T.N., et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008, 65:1596-1603.
10. Sheremata W.A., Vollmer T.L., Stone L.A., Willmer-Hulme A.J., Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. 1999, 52:1072-1074.
11. Hutchinson M., Natalizumab A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007, 3:259-268.
12. EMEA. EPARs for authorised medicinal products for human use. Scientific discussion. Tysabri [consultado 1-2-2010]. Disponible en: http://www.ema.europa.eu/humandocs/PDFs/EPAR/tysabri/H-603-en6.pdf.
13. O'Connor P.W., Goodman A., Willmer-Hulme A.J., Libonati M.A., Metz L., Murray R.S., et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004, 62:2038-2043.
14. Khatri B.O., Man S., Giovannoni G., Koo A.P., Lee J.C., Tucky B., et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009, 72:402-409.
15. Sweet B.V. Natalizumab update. Am J Health Syst Pharm. 2007, 64:705-716.
16. Kappos L., Bates D., Hartung H.P., Havrdova E., Miller D., Polman C.H., et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 2007, 6:431-441.
17. Tubridy N., Behan P.O., Capildeo R., Chaudhuri A., Forbes R., Hawkins C.P., et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 1999, 53:466-472.
18. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003, 348:15-23.
19. Goodman A.D., Rossman H., Bar-Or A., Miller A., Miller D.H., Schmierer K., et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009, 72:806-812.
20. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006, 354:899-910.
21. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006, 354:911-923.
22. Miller D.H., Soon D., Fernando K.T., MacManus D.G., Barker G.J., Yousry T.A., et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007, 68:1390-1401.
23. Havrdova E., Galetta S., Hutchinson M., Stefoski D., Bates D., Polman C.H., et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009, 8:254-260.
24. Hutchinson M., Kappos L., Calabresi P.A., Confavreux C., Giovannoni G., Galetta S.L., et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009, 256:405-415.
25. Balcer L.J., Galetta S.L., Calabresi P.A., Confavreux C., Giovannoni G., Havrdova E., et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007, 68:1299-1304.
26. Rudick R.A., Miller D., Hass S., Hutchinson M., Calabresi P.A., Confavreux C., et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007, 62:335-346.
27. Oturai A.B., Koch-Henriksen N., Petersen T., Jensen P.E., Sellebjerg F., Sorensen P.S. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009, 16:420-423.
28. Outteryck O., Ongagna J.C., Zéphir H., Fleury M.C., Lacour A., Blanc F., et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010, 257:207-211.
29. Putzki N., Yaldizli O., Maurer M., Cursiefen S., Kuckert S., Klawe C., et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol. 2009, 17:31-37.
30. Tedeschi G., Amato M.P., D'Alessandro R., Drago F., Milanese C., Popoli P., et al. The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci. 2009, 30(Suppl 2):S163-S165.
31. Putzki N., Yaldizli O., Buhler R., Schwegler G., Curtius D., Tettenborn B. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol. 2010, 63:101-106.
32. Calabresi P.A., Giovannoni G., Confavreux C., Galetta S.L., Havrdova E., Hutchinson M., et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007, 69:1391-1403.
33. EMEA. EPARs for authorised medicinal products for human use. Product information. Tysabri[consultado 1-2-2010]. Disponible en: http://www.ema.europa.eu/humandocs/PDFs/EPAR/tysabri/emea-combined-h603en.pdf.
34. Phillips J.T., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology. 2006, 67:1717-1718.
35. Krumbholz M., Pellkofer H., Gold R., Hoffmann L.A., Hohlfeld R., Kumpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007, 64:1331-1333.
36. Hellwig K., Schimrigk S., Fischer M., Haghikia A., Müller T., Chan A., et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol. 2008, 65:648-656.
37. Leussink V.I., Lehmann H.C., Hartung H.P., Gold R., Kieseier B.C. Type III systemic allergic reaction to natalizumab. Arch Neurol. 2008, 65:851-852. Author reply: 2.
38. Brown B.A. Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag. 2009, 5:585-594.
39. EMEA. EMEA/CHMP/145908/2008. Questions and answers on Tysabri liver injury. [consultado 1-2-2010]. Disponible en: http://www.ema.europa.eu/humandocs/PDFs/EPAR/tysabri/Q&A_Tysabri_14590808en.pdf.
40. Mullen J.T., Vartanian T.K., Atkins M.B. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med. 2008, 358:647-648.
41. Schweikert A., Kremer M., Ringel F., Liebig T., Duyster J., Stüve O., et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009, 66:403-406.
42. Álvarez-Cermeño J.C., García-Cosío M., Pérez de Oteyza J., Gasalla González T., Villar Guimerans L.M., Masjuán Vallejo J. Linfoma cerebral primario y tratamiento con natalizumab [abstract]. Neurología. 2008, 23:34-35.
43. Zecca C., Nessi F., Bernasconi E., Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology. 2009, 73:1418-1419.
44. Gutwinski S., Erbe S., Munch C., Janke O., Muller U., Haas J. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology. 2010, 74:521-523.
45. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005, 353:375-381.
46. Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005, 353:369-374.
47. Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005, 353:362-368.
48. Chaudhuri A. Lessons for clinical trials from natalizumab in multiple sclerosis. BMJ. 2006, 332:416-419.
49. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006, 354:924-933.
50. AEMPS. Nota informativa. Natalizumab (Tysabri®) y leucoencefalopatía multifocal progresiva: actualización de la información. [consultado 1-2-2010]. Disponible en: http://www.aemps.es/actividad/alertas/usoHumano/seguridad/2010/NI_2010-02_natalizumab_tysabri.htm.
51. FDA. Drug Safety Communication: risk of progressive multifocal leukoencephalopathy (LMP) with the use of Tysabri (natalizumab). [consultado 1-2-2010]. Disponible en: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm.
52. Jiang M., Abend J.R., Johnson S.F., Imperiale M.J. The role of polyomaviruses in human disease. Virology. 2009, 384:266-273.
53. Carson K.R., Focosi D., Major E.O., Petrini M., Richey E.A., West D.P., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009, 10:816-824.
54. Koralnik I.J. Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol. 2006, 60:162-173.
55. Pérez-Liz G., Del Valle L., Gentilella A., Croul S., Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol. 2008, 64:379-387.
56. Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin. 2008, 26:833-854. x-x10.
57. Sunyaev S.R., Lugovskoy A., Simon K., Gorelik L. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 2009, 5:e1000368.
58. Aksamit A.J. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist. 2006, 12:293-298.
59. SEN. Información para el médico y directrices para el manejo de pacientes con esclerosis múltiple en tratamiento con natalizumab. 3.a ed [consultado 1-2-2010]. Disponible en: http://www.sen.es/neuro/aut_pdf.php?path=pdf/2008/&fichero=natalizumab_3ed.pdf.
60. Stüve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006, 59:743-747.
61. Krumbholz M., Meinl I., Kumpfel T., Hohlfeld R., Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008, 71:1350-1354.
62. Zohren F., Toutzaris D., Klarner V., Hartung H.P., Kieseier B., Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008, 111:3893-3895.
63. Bonig H., Wundes A., Chang K.H., Lucas S., Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008, 111:3439-3441.
64. Sabath B.F., Major E.O. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002, 186(Suppl 2):S180-S186.
65. Monaco M.C., Atwood W.J., Gravell M., Tornatore C.S., Major E.O. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol. 1996, 70:1012-7004.
66. Hartung H.P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 2009, 8:28-31.
67. Tornatore C., Clifford D.B. Clinical vigilance for progressive multifocal leukoencephalopathy in the context of natalizumab use. Mult Scler 2009, 15:S16-S25.
68. Bartt R.E. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol. 2006, 19:341-349.
69. Rudick R.A., Panzara M.A. Natalizumab for the treatment of relapsing multiple sclerosis. Biologics. 2008, 2:189-199.
70. Wenning W., Haghikia A., Laubenberger J., Clifford D.B., Behrens P.F., Chan A., et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med. 2009, 361:1075-1080.
71. Tan K., Roda R., Ostrow L., McArthur J., Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009, 72:1458-1464.
72. Stüve O., Cravens P.D., Frohman E.M., Phillips J.T., Remington G.M., Von Geldern G., et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009, 72:396-401.
73. O'Connor P, Goodman A, Kappos L, Lublin FD, Miller DH, Polman CH, et al. Return of disease activity after cessation of natalizumab therapy in patients with multiple sclerosis (P793). Presentado en el 25th Congress of the European Committee For Treatment and Research In Multiple Sclerosis. 9 de Septiembre, 2009; Düsseldorf. 2010.
74. Vellinga M.M., Castelijns J.A., Barkhof F., Uitdejaag B.M.J., Polman C.H. Postwithdrawal rebound increase in T2 lesional activity in natalizumab treated MS patients. Neurology. 2008, 70:1150-1151.
75. Schiess N., Calabresi P.A. Natalizumab: bound to rebound? Neurology. 2009, 72:392-393.
76. Perumal J, Hreha S, Bao F, Zak I, Caon C, Tselis A, et al. Post-natalizumab associated rebound or CNS immune reconstitution syndrome: clinical and MRI findings (P418). Presentado en el 25th Congress of the European Committee For Treatment and Research In Multiple Sclerosis; 9 de Septiembre, 2009; Düsseldorf. 2010.